Stockscreener 앱 받기
33.42
2.14%
0.70
시간 외 거래:
33.42
전일 마감가:
$32.72
열려 있는:
$33.75
하루 거래량:
3,874
Relative Volume:
0.44
시가총액:
$3.11B
수익:
$136.33M
순이익/손실:
$-56.34M
주가수익비율:
-44.54
EPS:
-0.7504
순현금흐름:
$-18.87M
1주 성능:
-5.75%
1개월 성능:
-14.40%
6개월 성능:
+36.80%
1년 성능:
+0.00%
1일 변동 폭
$33.41
$33.95
1주일 범위
$32.68
$35.07
52주 변동 폭
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
AAPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
33.42 | 3.04B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-27 | 개시 | JP Morgan | Overweight |
Ascentage Pharma Group International Adr 주식(AAPG)의 최신 뉴스
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 82.7% in October - MarketBeat
Zymeworks’ Promising FRa ADC Potential: Buy Rating Affirmed by Analyst - TipRanks
Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position - TipRanks
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform - TipRanks
Pliant Therapeutics (PLRX) was downgraded to a Sell Rating at J.P. Morgan - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownHere's What Happened - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5%Here's What Happened - MarketBeat
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV) - The Globe and Mail
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 70.0% in September - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.5%Here's What Happened - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Here's Why Ascentage Pharma Group InternationalUnsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Ascentage Pharma to Engage with Investors at September Conferences - TipRanks
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week High – Should You Buy? - Defense World
Ascentage Pharma to Announce 2025 Interim Results and Corporate Update - The Globe and Mail
Ascentage Pharma to Engage in Evercore China Biotech Summit - TipRanks
Ascentage Pharma Completes Offshore Placement to Boost Global Operations - TipRanks
Ascentage Pharma Group International – Unsponsored ADR’s (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rd - Defense World
McGraw Hill, Inc. Plans $500 Million IPO for July 24th (MH) - Defense World
Gates Industrial (NYSE:GTES) Reaches New 1-Year High After Analyst Upgrade - Defense World
Accelerant Holdings (ARX) to Raise $551 Million in IPO - Defense World
Certara (NASDAQ:CERT) Trading Down 4.8% on Analyst Downgrade - Defense World
Diginex Stock Scheduled to Split on Friday, August 1st (NASDAQ:DGNX) - Defense World
Investors Purchase Large Volume of Call Options on Northern Trust (NASDAQ:NTRS) - Defense World
VerticalScope Holdings Inc. (TSE:FORA) Receives C$10.45 Consensus Price Target from Analysts - Defense World
Ascentage Pharma announces $192.3 million share placement By Investing.com - Investing.com South Africa
Ascentage Pharma announces $192.3 million share placement - Investing.com
Moser Wealth Advisors LLC Lowers Stake in NVIDIA Corporation (NASDAQ:NVDA) - Defense World
Ascentage Pharma Strengthens Leadership with Key Appointments - TipRanks
US Stocks Likely To Open Mixed As Trump Issues Tariff… - inkl
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' - Benzinga
Ascentage Pharma’s Studies to be Featured at 2025 EHA Congress - TipRanks
Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - marketscreener.com
Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025 - TipRanks
Ascentage Pharma Announces Successful AGM Resolutions on May 19, 2025 - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Ascentage Pharma Group International Adr (AAPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):